Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDSI NASDAQ:NKTR NASDAQ:OMER NASDAQ:PCRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDSIBioDelivery Sciences International$5.59$5.58$2.50▼$5.62$577.05M0.563.34 million shs2.09 million shsNKTRNektar Therapeutics$48.68+3.1%$28.01$6.45▼$50.53$897.68M1.061.10 million shs848,765 shsOMEROmeros$4.15-1.2%$3.97$2.95▼$13.60$285.84M2.37913,364 shs562,994 shsPCRXPacira BioSciences$27.12+0.3%$24.31$12.84▼$27.64$1.21B0.42604,000 shs601,903 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDSIBioDelivery Sciences International0.00%0.00%0.00%0.00%0.00%NKTRNektar Therapeutics0.00%+21.15%+82.39%+466.71%+159.63%OMEROmeros0.00%-0.48%+0.73%+22.06%+12.77%PCRXPacira BioSciences0.00%+2.53%+8.52%+11.88%+108.62%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDSIBioDelivery Sciences International$5.59$5.58$2.50▼$5.62$577.05M0.563.34 million shs2.09 million shsNKTRNektar Therapeutics$48.68+3.1%$28.01$6.45▼$50.53$897.68M1.061.10 million shs848,765 shsOMEROmeros$4.15-1.2%$3.97$2.95▼$13.60$285.84M2.37913,364 shs562,994 shsPCRXPacira BioSciences$27.12+0.3%$24.31$12.84▼$27.64$1.21B0.42604,000 shs601,903 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDSIBioDelivery Sciences International0.00%0.00%0.00%0.00%0.00%NKTRNektar Therapeutics0.00%+21.15%+82.39%+466.71%+159.63%OMEROmeros0.00%-0.48%+0.73%+22.06%+12.77%PCRXPacira BioSciences0.00%+2.53%+8.52%+11.88%+108.62%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDSIBioDelivery Sciences International 0.00N/AN/AN/ANKTRNektar Therapeutics 2.86Moderate Buy$88.3381.46% UpsideOMEROmeros 2.83Moderate Buy$18.00333.73% UpsidePCRXPacira BioSciences 2.71Moderate Buy$30.8313.69% UpsideCurrent Analyst Ratings BreakdownLatest BDSI, PCRX, NKTR, and OMER Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025OMEROmerosD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$36.008/15/2025OMEROmerosNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold8/15/2025OMEROmerosD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$36.008/14/2025PCRXPacira BioSciencesZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold7/25/2025OMEROmerosD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$36.007/25/2025PCRXPacira BioSciencesTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$30.007/8/2025NKTRNektar TherapeuticsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$60.00 ➝ $85.006/30/2025OMEROmerosD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$36.006/27/2025OMEROmerosHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.006/24/2025NKTRNektar TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$60.00 ➝ $100.006/24/2025NKTRNektar TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$120.00(Data available from 9/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDSIBioDelivery Sciences International$166.70M3.46$0.36 per share15.42$1.90 per share2.94NKTRNektar Therapeutics$98.43M9.41N/AN/A$4.94 per share9.85OMEROmerosN/AN/AN/AN/A($3.15) per shareN/APCRXPacira BioSciences$700.97M1.74$4.33 per share6.26$16.86 per share1.61Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDSIBioDelivery Sciences International$84.86M$0.836.748.47N/A50.90%21.25%10.56%N/ANKTRNektar Therapeutics-$118.96M-$8.80N/AN/AN/A-163.17%-631.43%-58.21%11/6/2025 (Estimated)OMEROmeros-$156.82M-$2.11N/AN/AN/AN/AN/A-55.49%11/12/2025 (Estimated)PCRXPacira BioSciences-$99.56M-$2.78N/A10.55N/A-18.08%13.29%6.61%11/5/2025 (Estimated)Latest BDSI, PCRX, NKTR, and OMER EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025OMEROmeros-$0.55-$0.53+$0.02-$0.43$0.31 million$28.60 million8/7/2025Q2 2025NKTRNektar Therapeutics-$3.13-$2.95+$0.18-$2.95$9.42 million$11.18 million8/5/2025Q2 2025PCRXPacira BioSciences$0.73$0.74+$0.01-$0.11$183.11 million$181.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBDSIBioDelivery Sciences InternationalN/AN/AN/AN/AN/ANKTRNektar TherapeuticsN/AN/AN/AN/AN/AOMEROmerosN/AN/AN/AN/AN/APCRXPacira BioSciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDSIBioDelivery Sciences International0.292.452.17NKTRNektar TherapeuticsN/A2.612.61OMEROmerosN/A0.810.81PCRXPacira BioSciences0.502.381.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDSIBioDelivery Sciences International64.40%NKTRNektar Therapeutics75.88%OMEROmeros48.79%PCRXPacira BioSciences99.73%Insider OwnershipCompanyInsider OwnershipBDSIBioDelivery Sciences International9.98%NKTRNektar Therapeutics5.25%OMEROmeros12.90%PCRXPacira BioSciences6.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDSIBioDelivery Sciences International200103.23 million92.93 millionOptionableNKTRNektar Therapeutics22019.02 million18.02 millionOptionableOMEROmeros21068.06 million59.28 millionOptionablePCRXPacira BioSciences72044.93 million42.06 millionOptionableBDSI, PCRX, NKTR, and OMER HeadlinesRecent News About These Companies51,764 Shares in Pacira BioSciences, Inc. $PCRX Bought by Caxton Associates LLPSeptember 12 at 5:36 AM | marketbeat.comJacobs Levy Equity Management Inc. Boosts Stock Position in Pacira BioSciences, Inc. $PCRXSeptember 9, 2025 | marketbeat.comPacira reports inducement grants under Nasdaq listing ruleSeptember 6, 2025 | msn.comBridgeway Capital Management LLC Buys 69,744 Shares of Pacira BioSciences, Inc. $PCRXSeptember 6, 2025 | marketbeat.comAlyeska Investment Group L.P. Takes $32.51 Million Position in Pacira BioSciences, Inc. $PCRXSeptember 6, 2025 | marketbeat.comRafferty Asset Management LLC Takes $251,000 Position in Pacira BioSciences, Inc. $PCRXSeptember 6, 2025 | marketbeat.comPacira BioSciences (NASDAQ:PCRX) Hits New 1-Year High - Here's What HappenedSeptember 5, 2025 | marketbeat.comPacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 5, 2025 | globenewswire.comPDT Partners LLC Has $5.14 Million Stock Position in Pacira BioSciences, Inc. $PCRXSeptember 3, 2025 | marketbeat.comPacira BioSciences, Inc. (NASDAQ:PCRX) Receives Consensus Rating of "Moderate Buy" from AnalystsSeptember 2, 2025 | marketbeat.comPacira BioSciences, Inc. $PCRX Shares Acquired by Doma Perpetual Capital Management LLCSeptember 1, 2025 | marketbeat.com9,457 Shares in Pacira BioSciences, Inc. $PCRX Acquired by FORA Capital LLCSeptember 1, 2025 | marketbeat.comPacira BioSciences, Inc. $PCRX Holdings Lifted by Walleye Capital LLCAugust 30, 2025 | marketbeat.comPacira BioSciences, Inc. $PCRX Shares Bought by Wellington Management Group LLPAugust 29, 2025 | marketbeat.comQuantbot Technologies LP Purchases 24,102 Shares of Pacira BioSciences, Inc. $PCRXAugust 28, 2025 | marketbeat.comMartingale Asset Management L P Takes Position in Pacira BioSciences, Inc. $PCRXAugust 27, 2025 | marketbeat.comAmerican Century Companies Inc. Increases Holdings in Pacira BioSciences, Inc. $PCRXAugust 27, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Grows Stock Holdings in Pacira BioSciences, Inc. $PCRXAugust 26, 2025 | marketbeat.comPacira BioSciences, Inc. $PCRX Shares Bought by Invesco Ltd.August 25, 2025 | marketbeat.comNuveen LLC Makes New Investment in Pacira BioSciences, Inc. $PCRXAugust 24, 2025 | marketbeat.comPacira BioSciences, Inc. $PCRX Shares Sold by Vanguard Group Inc.August 24, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBDSI, PCRX, NKTR, and OMER Company DescriptionsBioDelivery Sciences International NASDAQ:BDSIBioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. The company also provides ELYXYB, a celecoxib oral solution for the treatment of migraine with or without aura in adults; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina. As of March 18, 2022, BioDelivery Sciences International, Inc. operates as a subsidiary of Collegium Pharmaceutical, Inc.Nektar Therapeutics NASDAQ:NKTR$48.68 +1.48 (+3.14%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$48.40 -0.28 (-0.58%) As of 09/12/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.Omeros NASDAQ:OMER$4.15 -0.05 (-1.19%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$4.25 +0.10 (+2.41%) As of 09/12/2025 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.Pacira BioSciences NASDAQ:PCRX$27.12 +0.09 (+0.33%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$26.16 -0.96 (-3.52%) As of 09/12/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
